Subscribe
shutterstock_1066944104_siradawichitaphornkun
Sirada Wichitaphornkun / Shutterstock.com
21 August 2019AmericasSarah Morgan

Bayer to sell off animal health business for $7.6bn

Bayer has agreed to sell its animal health business to US-based Elanco Animal Health for $7.6 billion, as part of its strategic plan to focus on its core life sciences businesses.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Bayer buys BlueRock to build cell therapy expertise
9 August 2019   Bayer is set to acquire the rest of BlueRock Therapeutics, in a deal that values the Massachusetts-based cell therapy company at $1 billion.
Americas
BASF and Royal DSM embroiled in animal feed patent suits
16 April 2020   Bulgaria-based Huvepharma has accused chemicals company BASF and Dutch life sciences Koninklijke DSM, known as Royal DSM, of infringing its feed additive.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Bayer buys BlueRock to build cell therapy expertise
9 August 2019   Bayer is set to acquire the rest of BlueRock Therapeutics, in a deal that values the Massachusetts-based cell therapy company at $1 billion.
Americas
BASF and Royal DSM embroiled in animal feed patent suits
16 April 2020   Bulgaria-based Huvepharma has accused chemicals company BASF and Dutch life sciences Koninklijke DSM, known as Royal DSM, of infringing its feed additive.

More on this story

Americas
Bayer buys BlueRock to build cell therapy expertise
9 August 2019   Bayer is set to acquire the rest of BlueRock Therapeutics, in a deal that values the Massachusetts-based cell therapy company at $1 billion.
Americas
BASF and Royal DSM embroiled in animal feed patent suits
16 April 2020   Bulgaria-based Huvepharma has accused chemicals company BASF and Dutch life sciences Koninklijke DSM, known as Royal DSM, of infringing its feed additive.

More features

Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?
Pfizer infringed haemophilia therapy patent, says court
Cooley adds ex-Gowling partner